Latest Hotspot

Promising Results from Avidity's Phase 1/2 FORTITUDE™ Trial of AOC 1020: Over 50% DUX4 Gene Reduction and Functional Improvements in FSHD Patients

17 June 2024
3 min read

Avidity Biosciences, Inc., a biopharmaceutical firm focused on developing a novel category of RNA therapeutics known as Antibody Oligonucleotide Conjugates, revealed promising initial data from the Phase 1/2 FORTITUDE™ study of AOC 1020. The results showed unprecedented and consistent reductions exceeding 50% in DUX4 regulated genes, along with indications of functional enhancement and positive safety and tolerability outcomes for individuals with facioscapulohumeral muscular dystrophy.

👇Explore more about this drug by clicking the image below. Gain detailed insights into its R&D Status, Core Patent, Clinical Trials and Global Approval Status. Stay informed and updated.

Avidity intends to fast-track the start of registrational cohorts in its FORTITUDE™ trial. Additionally, Avidity has announced that the official international nonproprietary name for AOC 1020 will be delpacibart braxlosiran, abbreviated as del-brax. 

Del-brax represents the initial investigative therapy aimed at addressing the root cause of FSHD, a condition resulting from abnormal expression of the double homeobox 4 (DUX4) gene. FSHD is a rare hereditary disorder characterized by relentless and progressive muscle function loss, significant pain, fatigue, and increasing disability. Currently, there are no therapies approved for FSHD treatment.

"As the first therapy to target DUX4, the data on del-brax is promising, showing consistent reductions in DUX4-regulated genes and indicating potential functional improvements in FSHD patients at the four-month mark. These preliminary findings support the potential of del-brax to alter the disease trajectory for those with FSHD," remarked Jeffrey M. Statland, M.D., Professor of Neurology at the University of Kansas Medical Center and an investigator in the FORTITUDE™ trial.

Del-brax (AOC 1020) is engineered to tackle the root cause of FSHD, which stems from the anomalous expression of the DUX4 gene. The aberrant DUX4 protein expression results in altered gene expression in muscle cells, correlating with progressive muscle function decline in FSHD patients.

The objective of del-brax is to diminish the expression of DUX4 mRNA and DUX4 protein in the muscles of those with FSHD. Del-brax comprises a specialized monoclonal antibody that binds to the transferrin receptor 1 (TfR1), conjugated with a siRNA targeting DUX4 mRNA. Preclinical trials demonstrated that a single intravenous dose of the murine analog of del-brax prevented muscular weakness, as evidenced by three functional tests: treadmill running, in vivo force measurement, and compound muscle action potential assessment.

Del-brax is currently undergoing Phase 1/2 development as a component of the FORTITUDE™ study in adults with FSHD. It has received Orphan designation from both the U.S. Food and Drug Administration and the European Medicines Agency, while the FDA has also granted del-brax Fast Track designation.

👇Explore the latest research progress on drug-related developments, indications, therapeutic organizations, clinical trials, results, and patents by clicking on the targeted picture link below. Unfold a world of comprehensive information on this target in just a click!

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

According to the data provided by the Synapse Database, As of June 14, 2024, there are 1 investigational drugs for the DUX4 and TfR1 target, including 2 indications, 1 R&D institutions involved, with related clinical trials reaching 1, and as many as 110 patents.

AOC-1020 is an antibody oligonucleotide conjugate developed by Avidity Biosciences, Inc. for the treatment of various diseases, with a focus on Facioscapulohumeral Muscular Dystrophy 1a and 1B. The drug has reached Phase 1/2 in its development and has been granted Fast Track and Orphan Drug designations, underscoring its potential to address unmet medical needs in rare and serious conditions.

图形用户界面, 文本, 应用程序, 网站

描述已自动生成

Zumutor Biologics Reports First Patient Dosed with ZM008, an Innovative Anti-LLT1 Antibody
Latest Hotspot
3 min read
Zumutor Biologics Reports First Patient Dosed with ZM008, an Innovative Anti-LLT1 Antibody
17 June 2024
Zumutor Biologics Inc. has recently disclosed that the initial patient has been treated in its Phase 1 clinical trial with ZM008.
Read →
Nektar Therapeutics Presents Early Preclinical Results of TNFR2 Agonist NKTR-0165 at EULAR 2024
Latest Hotspot
3 min read
Nektar Therapeutics Presents Early Preclinical Results of TNFR2 Agonist NKTR-0165 at EULAR 2024
17 June 2024
Nektar Therapeutics Unveils Initial Preclinical Findings on NKTR-0165, a TNFR2 Agonist Antibody for Inflammatory Disease Therapy, at EULAR 2024.
Read →
FDA Approves Vivani Medical's NPM-119 GLP-1 Subdermal Implant and Lifts Clinical Hold
Latest Hotspot
3 min read
FDA Approves Vivani Medical's NPM-119 GLP-1 Subdermal Implant and Lifts Clinical Hold
17 June 2024
Vivani Medical Reports FDA Approval of New Drug Application and Removal of Clinical Hold for NPM-119, a Mini Subdermal GLP-1 Implant.
Read →
FDA Approves Kevzara® for Polyarticular Juvenile Idiopathic Arthritis Treatment
Latest Hotspot
3 min read
FDA Approves Kevzara® for Polyarticular Juvenile Idiopathic Arthritis Treatment
17 June 2024
The FDA has approved Kevzara® (sarilumab) for treating active polyarticular juvenile idiopathic arthritis (pJIA).
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.